Please note: This trial has finished recruiting and is not accepting new participants.

Research Center: Medical University of South Carolina
Location: 125 Doughty Street, Charleston, South Carolina
Lead Investigator: Dr. Michael Saladin
IRB Committee: This study has been reviewed and approved by the Medical University of South Carolina Institutional Review Board

Background

 

Recent research findings show that a medication known as Rapamycin – which is FDA-approved to treat organ rejection and some rare forms of lung disease – may also alter addiction-related memory in a way that decreases both the desire for drugs and drug use.

Therefore, the Medical University of South Carolina (MUSC) is conducting a related study to determine if Rapamycin can help in the treatment of smoking-related nicotine addiction.

This study seeks men and women who currently smoke and are looking to quit. Participants are required to attend 4 study visits at MUSC over a 3-week period; Participants will be compensated for participating in this study.

Why Participate? 

 

• You may see a reduction in your urge to smoke and/or smoking.
• You will receive appropriate professional referral depending on the outcome of your clinical assessment during study visits.
• You will be compensated for participating in this study.
• You will be helping to advance medical research.

Your Rights

 

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your health as it relates to the study.

Who Can Participate?

 

• Men and women aged 18+ who currently smoke and want to quit smoking.
• Able to attend 4 study visits at MUSC over approximately 3 weeks.
• Have no history of drug or alcohol abuse.
• Not currently undergoing smoking cessation treatments.